Improved Patient Outcomes and Cost-Effectiveness of CV Imaging

Sunday, April 3, 8-9:30 AM

It's all about outcomes and cost-effectiveness, but measuring outcomes in imaging studies can be tricky. Facilities and practices must first decide the parameters that can be reliably measured and benchmarked. They then must ensure these parameters can be reproduced across various enterprises and that the data can be mined intelligently.

The cost-effectiveness of a modality is inevitably linked with its ability to accurately rule in or rule out disease, thereby implementing the optimal therapeutic choice and reducing unnecessary downstream tests and costs. In this session, learn how to choose the parameters to measure and how echo, MRI, CT and nuclear imaging can contribute to your facility's standings in outcomes improvement.

Speaker Information
  • Michael S. Lauer, MD, National Heart, Lung and Blood Institute – What Parameters Should Be Used to Assess Improved Patient Outcomes and Cost-Effectiveness of Cardiovascular Imaging?
  • Thomas H. Marwick, MBBS, PhD, Cleveland Clinic – Echo Improves Patient Outcomes in a Cost-Effective Manner
  • James K. Min, MD, Weill-Cornell Medical College, NewYork-Presbyterian Hospital, N.Y. – CT Improves Outcomes in a Cost-Effective Manner
  • Christopher M. Kramer, MD, University of Virginia Health System, Charlottesville – CMR Improves Patient Outcomes in a Cost-Effective Manner
  • Rory Hachamovitch, MD, Cleveland Clinic – Nuclear Cardiology Improves Outcomes in a Cost-Effective Manner

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.